BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 2180497)

  • 1. Prognostic value of lymphocyte homing receptor and S phase fraction in non-Hodgkin's lymphoma.
    Jalkanen S; Joensuu H; Klemi P
    Blood; 1990 Apr; 75(7):1549-56. PubMed ID: 2180497
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of treatment on the prognostic value of S-phase fraction in non-Hodgkin's lymphoma.
    Joensuu H; Ristamäki R; Söderström KO; Jalkanen S
    J Clin Oncol; 1994 Oct; 12(10):2167-75. PubMed ID: 7931487
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic implications of ploidy and proliferative activity in the diffuse, aggressive non-Hodgkin's lymphomas.
    Winter JN; Andersen J; Variakojis D; Gordon LI; Fisher RI; Oken MM; Neiman RS; Jiang S; Bauer KD
    Blood; 1996 Nov; 88(10):3919-25. PubMed ID: 8916958
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biologic progression in non-Hodgkin's lymphoma. A flow cytometric study.
    Joensuu H; Klemi PJ; Jalkanen S
    Cancer; 1990 Jun; 65(11):2564-71. PubMed ID: 2337874
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic factors of stage I and II non-Hodgkin's lymphomas of the head and neck: the value of the working formulation and need for chemotherapy.
    Shigematsu N; Kondo M; Mikata A
    Int J Radiat Oncol Biol Phys; 1988 Nov; 15(5):1111-8. PubMed ID: 3182343
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of lymphocyte homing receptor antigen in non-Hodgkin's lymphoma.
    Picker LJ; Medeiros LJ; Weiss LM; Warnke RA; Butcher EC
    Am J Pathol; 1988 Mar; 130(3):496-504. PubMed ID: 2450463
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of S-phase fraction, working formulation, and Kiel classification in non-Hodgkin's lymphoma.
    Joensuu H; Klemi PJ; Söderström KO; Jalkanen S
    Cancer; 1991 Oct; 68(7):1564-71. PubMed ID: 1893358
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic relevance of ploidy and proliferative activity evaluation by flow cytometry in poor prognosis non-Hodgkin's lymphomas.
    De Lena M; Barletta A; Marzullo F; Lorusso V; Berardi F; Tommasi S; Mangia A; Paradiso A
    Haematologica; 1992; 77(1):84-6. PubMed ID: 1398287
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of radiotherapy dose and other treatment-related and clinical factors on in-field control in stage I and II non-Hodgkin's lymphoma.
    Kamath SS; Marcus RB; Lynch JW; Mendenhall NP
    Int J Radiat Oncol Biol Phys; 1999 Jun; 44(3):563-8. PubMed ID: 10348285
    [TBL] [Abstract][Full Text] [Related]  

  • 10. AgNORs predictive value of prognosis in non-Hodgkin's lymphoma: comparison with flow cytometric cell cycle analysis.
    Jakić-Razumović J; Uzarević B; Petrovecki M; Marusić M; Radman I; Labar B
    Leuk Lymphoma; 1992 May; 7(1-2):165-70. PubMed ID: 1472929
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lymphocyte homing and clinical behavior of non-Hodgkin's lymphoma.
    Jalkanen S; Joensuu H; Söderström KO; Klemi P
    J Clin Invest; 1991 May; 87(5):1835-40. PubMed ID: 2022749
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment and prognosis of orbital non-Hodgkin's lymphomas.
    Platanias LC; Putterman AM; Vijayakumar S; Recant W; Weichselbaum RR; Bitran JD
    Am J Clin Oncol; 1992 Feb; 15(1):79-83. PubMed ID: 1372464
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The chemoradiation treatment of patients with aggressive non-Hodgkin's lymphomas in the III-IV stages of the disease].
    Sotnikov VM; Pan'shin GA; Pivnik AV; Grigor'eva MA
    Ter Arkh; 1992; 64(7):54-6. PubMed ID: 1440370
    [No Abstract]   [Full Text] [Related]  

  • 14. DNA flow cytometry of non-Hodgkin's lymphomas: correlation with cytologic grade and clinical relapse.
    Saikia UN; Dey P; Vohra H; Gupta SK
    Diagn Cytopathol; 2000 Mar; 22(3):152-6. PubMed ID: 10679994
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pilot study of modified version of CHOP plus radiotherapy for early-stage aggressive non-Hodgkin's lymphoma of the head and neck.
    Nishioka T; Tsuchiya K; Nishioka S; Kitahara T; Ohmori K; Homma A; Aoyma H; Shindoh M; Shirato H
    Int J Radiat Oncol Biol Phys; 2004 Nov; 60(3):847-52. PubMed ID: 15465202
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor bulk as a prognostic factor for the management of localized aggressive non-Hodgkin's lymphoma: a survey of the Japan Lymphoma Radiation Therapy Group.
    Oguchi M; Ikeda H; Isobe K; Hirota S; Hasegawa M; Nakamura K; Sasai K; Hayabuchi N
    Int J Radiat Oncol Biol Phys; 2000 Aug; 48(1):161-8. PubMed ID: 10924986
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of involved field radiotherapy after CHOP-based chemotherapy on stage III-IV, intermediate grade and large-cell immunoblastic lymphomas.
    Schlembach PJ; Wilder RB; Tucker SL; Ha CS; Rodriguez MA; Hess MA; Cabanillas FF; Cox JD
    Int J Radiat Oncol Biol Phys; 2000 Nov; 48(4):1107-10. PubMed ID: 11072169
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Flow cytometric S-phase fraction as a complementary biological parameter for the cytological grading of non-Hodgkin's lymphoma.
    Pinto AE; Cabeçadas J; Nóbrega SD; Mendonça E
    Diagn Cytopathol; 2003 Oct; 29(4):194-9. PubMed ID: 14506670
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Defining the stages of aggressive non-Hodgkin's lymphoma--a work in progress.
    Armitage JO
    N Engl J Med; 2005 Mar; 352(12):1250-2. PubMed ID: 15788502
    [No Abstract]   [Full Text] [Related]  

  • 20. [Clinical features, treatment and prognosis of 136 patients with primary non-Hodgkin's lymphoma of the nasopharynx].
    Yuan ZY; Li YX; Zhao LJ; Gao YH; Liu XF; Gu DZ; Qian TN; Yu ZH
    Zhonghua Zhong Liu Za Zhi; 2004 Jul; 26(7):425-9. PubMed ID: 15355649
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.